• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    6.720 +0.170 (+2.60%)
    Streaming Delayed Price Updated: 1:27 PM EST, Feb 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 252,438
    Open 6.640
    Bid (Size) 6.720 (400)
    Ask (Size) 6.730 (300)
    Prev. Close 6.550
    Today's Range 6.631 - 6.860
    52wk Range 6.280 - 30.36
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Telix to Participate in Oppenheimer and TD Cowen Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Performance

    YTD
    -11.8%
    -11.8%
    1 Month
    -12.2%
    -12.2%
    3 Month
    -30.3%
    -30.3%
    6 Month
    -46.4%
    -46.4%
    1 Year
    -67.9%
    -67.9%

    More News

    Read More
    News headline image
    Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Full Year Results 2025 Investor Webcast Notification
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FRIDAY DEADLINE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
    From Berger Montague
    Via GlobeNewswire
    News headline image
    TLX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    UPCOMING DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Frequently Asked Questions

    Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
    Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
    What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
    Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
    The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
    What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
    The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 6.720
    When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
    The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 02/25/26 01:27 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.